Which medications in the drug class Antineoplastics, Other are used in the treatment of Colon Cancer?

Updated: Apr 15, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

Antineoplastics, Other

Larotrectinib selectively inhibits tropomyosin receptor kinases (TRKs). Entrectinib and its major metabolite TRKs, proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK). [172]  

Larotrectinib (Vitrakvi)

Highly selective inhibitor of tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC. In tumor models, larotrectinib demonstrates antitumor activity in cells by activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK overexpression

Entrectinib (Rozlytrek)

Selectively inhibits TRKA, TRKB, and TRKC. Indicated for adults and children aged 12 years or older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!